Prevention of fungal infections in the immunocompromised host

Area of Science:

• Mycology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Invasive fungal infections (IFIs) pose significant risks, increasing morbidity and mortality in immunocompromised populations.
• Current preventative antifungal strategies (prophylaxis, empirical, pre-emptive) are effective but linked to toxicity, high costs, and antifungal resistance.
• Optimizing antifungal use is crucial for managing IFIs in vulnerable patients.

Purpose of the Study:

• To review a risk-adjusted approach for antifungal agent use in preventing IFIs.
• To highlight the potential benefits of this strategy in cancer patients and other immunocompromised hosts.

Main Methods:

• Literature review focusing on risk-adjusted antifungal strategies.
• Analysis of the application of risk stratification in managing IFIs.
• Discussion of the advantages over traditional prophylactic, empirical, and pre-emptive approaches.

Main Results:

• A risk-adjusted strategy can personalize antifungal therapy, delivering benefits to high-risk patients while mitigating adverse effects in low-risk individuals.
• This approach aims to reduce toxicity, lower costs, and decrease the emergence of antifungal resistance.
• The strategy shows promise for application in cancer patients and potentially other immunocompromised groups.

Conclusions:

• Risk-adjusted antifungal strategies offer a promising alternative for managing IFIs in immunocompromised hosts.
• Personalized antifungal therapy can improve patient outcomes and resource utilization.
• Further research and implementation are warranted to validate and refine this approach.